Log In Sign up
The largest database of trusted experimental protocols

Female sho mice

Manufactured by Charles River Laboratories
Visit Supplier

Female SHO mice are a laboratory animal model provided by Charles River Laboratories. They are used for research purposes in controlled environments.

Automatically generated - may contain errors

Lab products found in correlation

In vivo xtreme imaging system, by Bruker (2 mentions) Mi software, by Bruker (2 mentions) Plx4720 formulated chow, by Research Diets (2 mentions) Ain 76a 417 mg kg, by Research Diets (2 mentions)

5 protocols using female sho mice

1

Xenograft Mouse Model of Caspase 3/7 Activity

Check if the same lab product or an alternative is used in the 5 most similar protocols
Female SHO mice (weight 20 to 27 g) were obtained from Charles River (Sulzfeld, Germany) and were 7 to 9 weeks of age at initiation of experiments. Four million D54-Caspase 3/7 GloSensor cells in 100 μl PBS were inoculated in the right flank of each mouse under 2% isofluran anesthesia. After 7 days, the animals were randomized in therapy groups (5 mice per group) according to their basal bioluminescent signal and their tumor volume. All animal studies were approved by the local government (file number 55.2-1-54-2532.2-26-09, Government of Upper Bavaria).
Weber T.G., Osl F., Renner A., Pöschinger T., Galbán S., Rehemtulla A, & Scheuer W. (2014). Apoptosis imaging for monitoring DR5 antibody accumulation and pharmacodynamics in brain tumors non-invasively. Cancer research, 74(7), 1913-1923.
+ Open protocol
+ Expand
2

Cy-peptide Analogues Biodistribution in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Female SHO mice (catalog no. 474; Charles River Laboratories) were administered with free Cyanine5.5 or Cy-peptide analogues (0.5 nmol of Cyanine5.5 content measured by UV absorbance at 680 nm) in a PBS solution (150 μL) via tail-vein injections (n = 4/group). Real-time fluorescence imaging was performed using an In Vivo Xtreme imaging system (Bruker). Whole body fluorescence images were acquired 1 and 4 hours postinjection using the appropriate excitation (670 nm) and emission (750 nm) filters. The animals were then euthanized. The organs were excised to perform ex vivo fluorescence imaging. Imaging was also performed on urine samples (20 μL) collected from separate animals 1, 4, and 6 hours after intravenous injection of free dye or Cy-peptide analogues (n = 4/treatment). Bruker MI software was used to process the fluorescence/bright light images and measure the fluorescence intensity in different ROIs. All the data were corrected to eliminate the organ or fluid auto-fluorescence.
Bellat V., Michel A.O., Thomas C., Stokol T., Choi B.B, & Law B. (2022). A Urinary Drug-Disposing Approach as an Alternative to Intravesical Chemotherapy for Treating Nonmuscle Invasive Bladder Cancer. Cancer Research, 82(7), 1409-1422.
+ Open protocol
+ Expand
3

Evaluating PLX4720 and GDC-0941 in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
All animal studies were carried out under approved protocols by the Institutional Animal Care and Use Committee at the University of South Florida. Female SHO mice (Charles River) were subcutaneously injected with 2.5 ×106 cells per mouse. Tumors were allowed to grow to approximately 100mm3. Mice were administered D10001 control chow, AIN-76A 417 mg/kg PLX4720-formulated chow (Research Diets, New Brunswick, NJ), vehicle (0.5% methylcellulose, 0.2% Tween-80) oral gavage, or GDC-0941 oral gavage (150mg/kg) daily for 8 days. Mouse tumor volumes (1/2 × L × W2) were measured.
Fedorenko I.V., Wargo J.A., Flaherty K.T., Messina J.L, & Smalley K.S. (2015). BRAF inhibition generates a host/tumor niche that mediates therapeutic escape. The Journal of investigative dermatology, 135(12), 3115-3124.
+ Open protocol
+ Expand
4

In Vivo Fluorescence Imaging of Cyanine5.5 and Cy-peptide Analogues

Check if the same lab product or an alternative is used in the 5 most similar protocols
Female SHO mice (Cat# 474, Charles River Laboratories, Wilmington, MA) were administered with free Cyanine5.5 or Cy-peptide analogues (0.5 nmol of Cyanine5.5 content measured by UV absorbance at 680 nm) in a PBS solution (150 μL) via tail-vein injections (n=4/group). Real-time fluorescence imaging was performed using an In Vivo Xtreme imaging system (Bruker, Billerica, MA). Whole body fluorescence images were acquired 1 and 4 h post injection using the appropriate excitation (670 nm) and emission (750 nm) filters. The animals were then euthanized. The organs were excised to perform ex vivo fluorescence imaging. Imaging was also performed on urine samples (20 μL) collected from separate animals 1, 4, and 6 h after i.v. injection of free dye or Cy-peptide analogues (n=4/treatment). Bruker MI software was used to process the fluorescence/bright light images and measure the fluorescence intensity in different ROIs. All the data were corrected to eliminate the organ or fluid auto-fluorescence.
Bellat V., Michel A.O., Thomas C., Stokol T., Choi B.B, & Law B. (2022). A Urinary Drug-Disposing Approach as an Alternative to Intravesical Chemotherapy for Treating Nonmuscle Invasive Bladder Cancer. Cancer Research, 82(7), 1409-1422.
+ Open protocol
+ Expand
5

Evaluating PLX4720 and GDC-0941 in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
All animal studies were carried out under approved protocols by the Institutional Animal Care and Use Committee at the University of South Florida. Female SHO mice (Charles River) were subcutaneously injected with 2.5 ×106 cells per mouse. Tumors were allowed to grow to approximately 100mm3. Mice were administered D10001 control chow, AIN-76A 417 mg/kg PLX4720-formulated chow (Research Diets, New Brunswick, NJ), vehicle (0.5% methylcellulose, 0.2% Tween-80) oral gavage, or GDC-0941 oral gavage (150mg/kg) daily for 8 days. Mouse tumor volumes (1/2 × L × W2) were measured.
Fedorenko I.V., Wargo J.A., Flaherty K.T., Messina J.L, & Smalley K.S. (2015). BRAF inhibition generates a host/tumor niche that mediates therapeutic escape. The Journal of investigative dermatology, 135(12), 3115-3124.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!